Stem Cell Therapies for Reversing Vision Loss
Trends in Biotechnology, ISSN: 0167-7799, Vol: 35, Issue: 11, Page: 1102-1117
2017
- 50Citations
- 107Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations50
- Citation Indexes49
- 49
- CrossRef37
- Patent Family Citations1
- Patent Families1
- Captures107
- Readers107
- 107
Review Description
Current clinical trials that evaluate human pluripotent stem cell (hPSC)-based therapies predominantly target treating macular degeneration of the eyes because the eye is an isolated tissue that is naturally weakly immunogenic. Here, we discuss current bioengineering approaches and biomaterial usage in combination with stem cell therapy for macular degeneration disease treatment. Retinal pigment epithelium (RPE) differentiated from hPSCs is typically used in most clinical trials for treating patients, whereas bone marrow mononuclear cells (BMNCs) or mesenchymal stem cells (MSCs) are intravitreally transplanted, undifferentiated, into patient eyes. We also discuss reported negative effects of stem cell therapy, such as patients becoming blind following transplantation of adipose-derived stem cells, which are increasingly used by ‘stem-cell clinics’.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0167779917301658; http://dx.doi.org/10.1016/j.tibtech.2017.06.016; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85025475102&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/28751147; https://linkinghub.elsevier.com/retrieve/pii/S0167779917301658; https://dx.doi.org/10.1016/j.tibtech.2017.06.016
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know